Common genetic link between autism and Tourette's impairs brain communication

December 09, 2019

Lancaster University researchers have discovered, for the first time, how a genetic alteration that increases the risk of developing Autism and Tourette's impacts on the brain.

Their research also suggests that ketamine, or related drugs, may be a useful treatment for both of these disorders.

Autism affects an estimated 2.8 million people in the UK while Tourette's Syndrome - a condition that causes a person to make involuntary sounds and movements called tics -affects an estimated 300,000 people in the UK. The treatments available for both disorders are limited and new treatments are urgently required. Recent research has also shown that these disorders are genetically linked.

People with a genetic deletion known as chromosome 2p16.3 deletion often experience developmental delay and have learning difficulties. They are also around 15 times more likely to develop Autism and 20 times more likely to develop Tourette's Syndrome, but the mechanisms involved are not completely understood.

Using brain imaging studies, neuroscientists have shown that deletion of the gene impacted by 2p16.3 deletion (Neurexin1) impacts on the function of brain regions involved in both conditions. A key finding is that this genetic deletion disrupts a brain area known as the thalamus, compromising its ability to communicate with other brain areas.

Lead researcher Dr Neil Dawson of Lancaster University said: "We currently have a very poor understanding of how the 2p16.3 deletion dramatically increases the risk of developing these disorders.

However, we know that the 2p16.3 deletion involves deletion of the Neurexin1 gene, a gene that makes a protein responsible for allowing neurons to communicate effectively."

Deletion of the Neurexin1 gene affects brain areas involved in Autism and Tourette's including the thalamus, a collection of brain regions that play a key role in helping other brain areas communicate with each other. Changes were also found in brain regions involved in processing sensory information and in learning and memory.

Importantly, the researchers also found that the ability of the thalamic brain regions to communicate with other brain areas was impaired by the genetic deletion. They then tested the ability of a low dose of the drug ketamine, a drug used clinically at higher doses as an anesthetic, to normalize the alterations in brain function induced by the genetic deletion.

Dr Dawson said: "Intriguingly our data suggest that ketamine can restore some aspects of the brain dysfunction that results from 2p16.3 deletion and suggests that ketamine, or other related drugs, may be useful in treating some of the symptoms seen in Autism and Tourette's. The brain circuits affected suggest that these drugs may be particularly useful for the cognitive and motor problems experienced by people with these disorders."

Interestingly, ketamine was shown to normalise activity in the thalamic regions found to be hyperactive as a result of the genetic deletion and re-established the ability of these regions to communicate with other brain areas. This suggests that ketamine, or related drugs, may be a useful treatment for people with 2p16.3 deletion or with Autism and Tourette's Syndrome, although more research is needed.

Dr Dawson urges caution to those who may be thinking of using ketamine therapeutically.

"While this data gives us important new information on the brain circuits affected by 2p16.3 deletion and of the potential usefulness of ketamine to help people with Autism and Tourette's much more research needs to be conducted to prove its clinical potential. We know that ketamine impacts on the activity of several brain regions in addition to the thalamus, and the effects in these other regions are likely to cause unwanted side-effects. In addition, long-term ketamine treatment may have negative consequences that are not yet fully understood. We also think ketamine may not be the best therapeutic option due to its relatively short lifespan in the body.

"However, the findings of this study give us important clues regarding the types of drugs that may be useful in the treatment of these disorders, and we are using this information to actively pursue the validation of these drugs for the potential treatment of these disorders."

Lancaster University

Related Autism Articles from Brightsurf:

Autism-cholesterol link
Study identifies genetic link between cholesterol alterations and autism.

National Autism Indicators Report: the connection between autism and financial hardship
A.J. Drexel Autism Institute released the 2020 National Autism Indicators Report highlighting the financial challenges facing households of children with autism spectrum disorder (ASD), including higher levels of poverty, material hardship and medical expenses.

Autism risk estimated at 3 to 5% for children whose parents have a sibling with autism
Roughly 3 to 5% of children with an aunt or uncle with autism spectrum disorder (ASD) can also be expected to have ASD, compared to about 1.5% of children in the general population, according to a study funded by the National Institutes of Health.

Adulthood with autism
The independence that comes with growing up can be scary for any teenager, but for young adults with autism spectrum disorder and their caregivers, the transition from adolescence to adulthood can seem particularly daunting.

Brain protein mutation from child with autism causes autism-like behavioral change in mice
A de novo gene mutation that encodes a brain protein in a child with autism has been placed into the brains of mice.

Autism and theory of mind
Theory of mind, or the ability to represent other people's minds as distinct from one's own, can be difficult for people with autism.

Potential biomarker for autism
A study of young children with autism spectrum disorder published in JNeurosci reveals altered brain waves compared to typically developing children during a motor control task.

Autism often associated with multiple new mutations
Most autism cases are in families with no previous history of the disorder.

State laws requiring autism coverage by private insurers led to increases in autism care
A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health has found that the enactment of state laws mandating coverage of autism spectrum disorder (ASD) was followed by sizable increases in insurer-covered ASD care and associated spending.

Autism's gender patterns
Having one child with autism is a well-known risk factor for having another one with the same disorder, but whether and how a sibling's gender influences this risk has remained largely unknown.

Read More: Autism News and Autism Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to